Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder [4]

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 317-319

  Bailey, Darrin L ^a   Le Mellédo, Jean Michel ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CITALOPRAM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; EATING HABIT; EXERCISE; HUMAN; LETTER; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 0037708006     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200306000-00016     Document Type: Letter

References (19)

1. Weissman MM, Markowitz JS, Oulette R, et al. Panic disorder and cardiovascular/cerebrovascular problems: Results from a community survey. Am J Psychiatry. 1990;147: 1504-1508.
2. Kawachi I, Sparrow D, Vokonas PS, et al. Symptoms of anxiety and risk of coronary heart disease: the Normative Aging Study. Circulation. 1994a;90:2225-2229.
3. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and the implications for therapy. Cardiology. 1999; 99:2192-2217.
4. Hayward C, Taylor CB, Roth WT, et al. Plasma lipid levels in patients with panic disorder or agoraphobia. Am J Psychiatry. 1989;146:917-919.
5. Tancer ME, Stein MB, Moul DE, et al. Normal serum cholesterol in panic disorder. Biological Psychiatry. 1990;27:99-101.
6. Yeragani VK, Pohl R, Balon R, et al. Risk factors for cardiovascular illness in panic disorder patients. Neuropsychobiology. 1990; 23:134-139.
7. Bajwa WK, Asnis GM, Sanderson WC, et al. High cholesterol levels in patients with panic disorder. Am J Psychiatry. 1992;149: 376-378.
8. Reifman A, Windle M. High cholesterol levels in patients with panic disorder [letter]. Am J Psychiatry. 1993;150:527.
9. Agargun MY, Kara H, Algun E, et al. High cholesterol levels in patients with sleep panic. Biological Psychiatry. 1996;40:1064-1065.
10. Yamada K, Tsutsumi T, Fujii AI. Serum cholesterol levels in patients with panic disorders: a comparison with major depression and schizophrenia. Psychiatry Clin Neurosci. 1997;51:31-34.
11. Lacerda ALT, Caetano D, Caetano SC. Cholesterol levels in panic disorder, generalized anxiety disorder and major depression. Arquivos de Neuro-Psiquiatria. 2000; 58(2-B):408-411.
12. Liebowitz MR, Mangano RM. Venlafaxine XR in Generalized Social Anxiety Disorder. In: Proceedings of the 42nd Annual NCDEU Meeting (Boca Raton, FL). 2002.
13. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61:863-867.
14. Zaubler TS, Katon W. Panic disorder and medical comorbidity: a review of the medical and psychiatric literature. Bulletin of the Menninger Clinic. 1996;2(Suppl A):A12-A38.
15. Haines AP, Imeson JD, Meade TW. Phobic anxiety and ischaemic heart disease. BMJ (Clinical Research Edition). 1987;295: 297-299.
16. Chignon JM, Lepine JP, Ades J. Panic disorder in cardiac outpatients. Am J Psychiatry. 1993;150:780-785.
17. Goldberg R, Morris P, Christian F, et al. Panic disorder in cardiac outpatients. Psychosomatics. 1990;31:168-173.
18. Morris A, Baker B, Devins GM, et al. Prevalence of panic disorder in cardiac outpatients. Can J Psychiatry. 1997;42:185-190.
19. National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.